ISIS 15999
Alternative Names: Bcl-x antisense oligonucleotides - ISISLatest Information Update: 11 Jul 2006
At a glance
- Originator Isis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Bcl-X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Jul 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 08 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)
- 30 Aug 2002 No development reported - Preclinical for Cancer in USA (unspecified route)